Form 483

Kelley-Ross & Associates, Inc. dba Kelley-Ross Compounding Pharmacy Form 483, 2020-09-23

FDA issued a Form 483 to Kelley-Ross & Associates, Inc. dba Kelley-Ross Compounding Pharmacy on 2020-09-23 with 5 public-safe observations.

483· Form 483 issuedHuman Drugs5 observations

Kelley-Ross & Associates, Inc. dba Kelley-Ross Compounding Pharmacy · Seattle, United States · Issued September 23, 2020

Overview

  • 5 public-safe observations are available for this inspection.
  • 1 structured CFR citation is represented.
  • 1 investigator is tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

23 Sep 2020
FDCA 501(a)(2)(A)

Air flow quality, higher classified area

Cited by Christopher R Czajka

23 Sep 2020
FDCA 501(a)(2)(A)

Cleanliness, ISO-classified areas

Cited by Christopher R Czajka

23 Sep 2020
FDCA 501(a)(2)(A)

Disinfecting materials, aseptic processing area

Cited by Christopher R Czajka

23 Sep 2020
FDCA 501(a)(2)(A)

Hazardous drugs, prevention of cross-contamination

Cited by Christopher R Czajka

23 Sep 2020
FDCA 501(a)(2)(A)

Improper gowning, contamination

Cited by Christopher R Czajka

Inspected site

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
FDCA 501(a)(2)(A)Cited across public-safe Form 483 observations5x

Source document

PDF
PDF available

Form 483 source document

The source document is available to authorized Atlas users.

Full 483 report

Get the verbatim text of all 5 observations

The source PDF, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere